BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2022 12:06:56 PM | Browse: 829 | Download: 1878
Publication Name World Journal of Clinical Cases
Manuscript ID 73844
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Hematology
Manuscript Type Case Report
Article Title Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report
Manuscript Source Unsolicited Manuscript
All Author List Hai-Ping Liang, Xing-Chun Luo, Ya-Li Zhang and Bei Liu
ORCID
Author(s) ORCID Number
Hai-Ping Liang http://orcid.org/0000-0001-7537-278X
Xing-Chun Luo http://orcid.org/0000-0002-4576-9011
Ya-Li Zhang http://orcid.org/0000-0002-4176-9129
Bei Liu http://orcid.org/0000-0003-4331-2138
Funding Agency and Grant Number
Corresponding Author Bei Liu, MD, PhD, Professor, Department of Hematology, The First Affiliated Hospital, Lanzhou University, No. 1 Donggangxi Road, Chengguan District, Lanzhou 730000, Gansu Province, China. liubeiff@163.com
Key Words Myelodysplastic syndrome; Del(5q); Inv(3); Lenalidomide; Azacitidine; Case report
Core Tip We report a rare case of myelodysplastic syndrome (MDS) with two chromosomal structural abnormalities, del(5q) and inv(3). The patient evolved from the initial del(5q) to inv(3) combined with del(5q). Considering the deletion of chromosome 5q, we first treated the patient with lenalidomide. When drug resistance arose, we tried azacitidine, and the patient had a short remission. Finally, the patient refused treatment with haematopoietic stem cell transplantation (HSCT), and her condition gradually deteriorated until she was discharged from the hospital. In this rare and contradictory situation, we found that MDS patients with coexisting del(5q) and inv(3) may have a poor prognosis. However, azacitidine may play a role to some extent in MDS with del(5q) and inv(3), and HSCT may be the only way to cure the disease.
Publish Date 2022-04-08 12:06
Citation Liang HP, Luo XC, Zhang YL, Liu B. Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report. World J Clin Cases 2022; 10(11): 3601-3608
URL https://www.wjgnet.com/2307-8960/full/v10/i11/3601.htm
DOI https://dx.doi.org/10.12998/wjcc.v10.i11.3601
Full Article (PDF) WJCC-10-3601.pdf
Full Article (Word) WJCC-10-3601.docx